Compare QNRX & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QNRX | GXAI |
|---|---|---|
| Founded | 2018 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5M | 11.7M |
| IPO Year | 2023 | 2022 |
| Metric | QNRX | GXAI |
|---|---|---|
| Price | $5.68 | $1.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 113.6K | ★ 779.7K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 71.35 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,933,030.00 |
| Revenue This Year | N/A | $79.41 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 47901.74 |
| 52 Week Low | $5.27 | $1.00 |
| 52 Week High | $41.80 | $2.96 |
| Indicator | QNRX | GXAI |
|---|---|---|
| Relative Strength Index (RSI) | 36.22 | 47.77 |
| Support Level | N/A | $1.22 |
| Resistance Level | $10.42 | $1.31 |
| Average True Range (ATR) | 0.96 | 0.08 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 5.04 | 42.59 |
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.